AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studySystematic reviewPublished in a peer-reviewed journal
High-Dose Biotin Effects on MS Patients
High-dose biotin (≥ 300 mg/day) was found to lack clinical benefits for treating progressive multiple sclerosis (MS) in a large phase 3 trial, contrary to initial reports. Some MS patients taking biotin were misdiagnosed with Graves' disease or hyperthyroidism, but their thyroid functions normalized after stopping biotin.
- Tags
- #Other
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not demonstrated in people
- Mechanism
- Not reported
- Evidence strength
- Moderate
- Outcome
- Negative
Why it matters
The findings highlight that high-dose biotin is not an approved treatment for MS and can lead to misinterpretation of thyroid lab results, which is crucial for accurate autoimmune diagnoses.
What this does not prove
The review confirms a lack of clinical efficacy for biotin in MS and unknown thyroid effects in non-MS patients, complicating its use as a treatment.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- All
- Publication date
- 2026-10-10
- Evidence reviewed
- Abstract only
- Regulatory approval
- No
- Research areas
- Other
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- patients with MS and hair loss conditions, such as alopecia areata
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceThe implications of biotin supplementation on multiple sclerosis, hair loss conditions, and thyroid disorders. ↗DOI: 10.1016/j.msard.2026.107974
Supporting passages (13)
study designPublication types: Journal Article; Review
regulatory approvaland it is not an approved therapy for MS.
research categoriesThis review integrates neurological and dermatological autoimmune overlap in the context of biotin interference and addresses an underexplored gap in the literature.
relevant ms typesconditions frequently coexisting with thyroid dysfunction, may be vulnerable to misinterpretation of thyroid lab results due to biotin supplementation.
publication datePublication date: 2026-10-10
interventionbiotin supplementation.
findingsSeveral case reports illustrate patients with MS misdiagnosed with Graves' disease or hyperthyroidism while taking high-dose biotin, with laboratory values normalizing after temporary discontinuation.
limitationsHigh-dose biotin (≥ 300 mg/day) has also been studied as a treatment for progressive multiple sclerosis (MS), although the clinical benefit reported in an initial randomized trial was not confirmed in a larger phase 3 trial, and it is not an approved therapy for MS.
populationIn this narrative review of clinical studies and case reports, we found that patients with MS and hair loss pathology, such as alopecia areata (AA), conditions frequently coexisting with thyroid dysfunction, may be vulnerable to misinterpretation of thyroid lab results due to biotin supplementation.
outcomeHigh-dose biotin (≥ 300 mg/day) has also been studied as a treatment for progressive multiple sclerosis (MS), although the clinical benefit reported in an initial randomized trial was not confirmed in a larger phase 3 trial, and it is not an approved therapy for MS.
human efficacyHowever, increasing evidence suggests that biotin supplementation, even at over-the-counter doses of 5-20 mg/day, can interfere with thyroid function tests, leading to potential misdiagnoses of hyperthyroidism and autoimmune thyroid disease.
peer reviewedPublication types: Journal Article; Review
subjectsIn this narrative review of clinical studies and case reports, we found that patients with MS and hair loss pathology, such as alopecia areata (AA), conditions frequently coexisting with thyroid dysfunction, may be vulnerable to misinterpretation of thyroid lab results due to biotin supplementation.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.